# Kobiolabs

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kobiolabs

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.kobiolabs.com
- Total disclosed funding: $8.7M
- Latest round: Series B (Jul 7, 2017)
- Investors on record: 3

## About

Founded in 2014 and based in Seoul, South Korea, Kobiolabs is a biotechnology company that focuses on developing microbiome therapeutics for immune, metabolic and neurological. The diff infection program, atopic dermatitis program, and chronic kidney disease program are selected as the government-sponsored project in 2017. The candidate drug for psoriasis, KBLP-001 phases 1 study HREC approve in 2019, and phase 1 study completed in May 2020. The candidate drug for Inflammatory Bowel Disease (IBD) was initiated in April 2020 and received phase two study approval from the US in July 2021. The company was listed on the KOSDAQ stock market in November 2020.  

The company engages in microbiome therapeutics for immune, metabolic and neurological. The new drug development pipeline has entered clinical phases including candidates for drugs for psoriasis, asthma, and IBD. And the candidate's drugs for immune-oncology, liver disease, autism spectrum disorder non-alcoholic steatohepatitis are in the development phase.

## Funding rounds

- Series B, Jul 7, 2017, $8.7M — Atinum Investment, Company K Partners, Stonebridge Ventures

## Investors

- Atinum Investment (https://capitalatlas.ai/funds/atinum-investment) — Series B
- Company K Partners (https://capitalatlas.ai/funds/company-k-partners) — Series B
- Stonebridge Ventures — Series B